Sugi Predict

Sugi Predict / Targets / CD4

CD4

T-cell surface glycoprotein CD4 · P01730 · CD4 on Sugi Atlas →

2,100 patent compounds predicted against CD4, 757 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Hydrochloric Acid Hydrochloric Acid (SCHEMBL21358957) 0.53 19/20
SCHEMBL4108387 SCHEMBL4108387 0.67 18/20
SCHEMBL13925186 SCHEMBL13925186 0.66 18/20
SCHEMBL13925190 SCHEMBL13925190 0.64 18/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL21358940) 0.55 18/20
SCHEMBL21361518 SCHEMBL21361518 0.54 18/20
SCHEMBL21361591 SCHEMBL21361591 0.52 18/20
SCHEMBL13925181 SCHEMBL13925181 0.69 17/20
SCHEMBL13925185 SCHEMBL13925185 0.69 17/20
SCHEMBL4273230 SCHEMBL4273230 0.67 17/20
SCHEMBL13925188 SCHEMBL13925188 0.67 17/20
SCHEMBL13925184 SCHEMBL13925184 0.66 17/20
SCHEMBL4268084 SCHEMBL4268084 0.65 17/20
SCHEMBL13925189 SCHEMBL13925189 0.60 17/20
SCHEMBL21361626 SCHEMBL21361626 0.59 17/20
SCHEMBL21361467 SCHEMBL21361467 0.53 17/20
SCHEMBL13925206 SCHEMBL13925206 0.67 16/20
SCHEMBL13925179 SCHEMBL13925179 0.64 16/20
SCHEMBL21361515 SCHEMBL21361515 0.56 16/20
SCHEMBL13983878 SCHEMBL13983878 0.51 16/20

Clinical trials — most relevant to CD4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases PHASE4ENROLLING_BY_INVITATION
Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis PHASE4COMPLETED
Latency in Pulmonary Tuberculosis PHASE3COMPLETED
Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant PHASE1/PHASE2COMPLETED
Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) PHASE2RECRUITING
Salt-Sensitivity and Immunity Cell Activation PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans PHASE2NOT_YET_RECRUITING
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) PHASE1/PHASE2COMPLETED
Immune and Viral Outcomes of HIV-1 Therapy Interruption PHASE1COMPLETED
Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals PHASE1COMPLETED
A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex PHASE1COMPLETED
Dose Escalation Study of Immunomodulatory Nanoparticles PHASE1ACTIVE_NOT_RECRUITING
Adoptive Transfer of Haploidentical NK Cells and N-803 PHASE1COMPLETED
Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB. PHASE1COMPLETED
Expansion of Virus-Specific Lymphocytes for Cell Therapy PHASE1RECRUITING
CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies PHASE1UNKNOWN
Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serum Biomarkers and on PBMCs in Breast Cancer Surgery nanWITHDRAWN
COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics nanRECRUITING
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED
Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia. nanUNKNOWN
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection nanRECRUITING
Precision Physical Exercise for Personalized Onco-Hematology. nanNOT_YET_RECRUITING
Observation in the Treatment of Graves' Disease nanUNKNOWN
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
Fish Oil for HIV-Related Inflamm-aging and Immune Senescence nanCOMPLETED
Characterization of HIV-1 Reservoirs in HIV-1 Non-B Infected Adolescents on ART in Cameroon nanCOMPLETED
Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background nanWITHDRAWN
Association of Nutrition and T Cell Immune Activity With Disease Progression in Nontuberculous Mycobacterial Pulmonary Disease nanNOT_YET_RECRUITING
Observation on the Treg in the Uveitis Patients nanCOMPLETED
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CD4 binder may also engage these)

ProteinNameSimilarity
P16004 — 1.000 P16004 →
P16003 — 1.000 P16003 →
P79184 — 1.000 P79184 →
P79185 — 1.000 P79185 →
Q9XS78 — 1.000 Q9XS78 →
Q08338 — 1.000 Q08338 →
Q08340 — 1.000 Q08340 →
Q08339 — 1.000 Q08339 →
P06332 — 1.000 P06332 →
Q08336 — 1.000 Q08336 →
Q29037 — 1.000 Q29037 →
P33705 — 0.997 P33705 →
P46630 — 0.996 P46630 →
P05540 — 0.995 P05540 →
P97710 — 0.984 P97710 →
P04218 — 0.983 P04218 →
O00241 — 0.983 O00241 →
CD2 T-cell surface antigen CD2 0.983 landscape →
P08920 — 0.982 P08920 →
Q9P1W8 — 0.982 Q9P1W8 →
Q9N1E5 — 0.981 Q9N1E5 →
Q9QUM4 — 0.980 Q9QUM4 →
P43121 — 0.980 P43121 →
P01731 — 0.980 P01731 →
P48095 — 0.980 P48095 →
P29460 — 0.979 P29460 →
Q865W9 — 0.979 Q865W9 →
D3YX43 — 0.979 D3YX43 →
P97797 — 0.979 P97797 →
Q07763 — 0.979 Q07763 →